Certara is the leading drug development consultancy with solutions spanning the discovery, preclinical and clinical stages of drug development.
PRINCETON, NJ – Mar. 13, 2018 – Certara today announced the launch of its Quantitative Systems Pharmacology (QSP) Immuno-oncology Simulator Consortium.
PRINCETON, NJ – Mar. 12, 2018 – Certara today announced that it is partnering with faculty at the UNC Eshelman School of Pharmacy to launch the Model-informed Drug Development (MIDD) Gran Prix at the 2018 American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting.
PRINCETON, NJ – Feb. 27, 2018 – Certara today announced that it has published two papers demonstrating proof of concept for its Virtual Twin™ technology.
PRINCETON, NJ – Feb. 14, 2018 – Certara today announced the launch of version 10 of D360, its data informatics platform for discovery scientists. D360 is a self-service data access, integration and visualization solution used to query diverse cheminformatics and bioinformatics data sources to make informed go/no go research decisions.
PRINCETON, NJ – Feb. 1, 2018 – Certara today announced that it has acquired BaseCase Management GmbH, a data visualization software as a service (SaaS) company headquartered in Berlin, Germany, with offices in New York.
PRINCETON, NJ – January 17, 2018 – Certara today announced that the Brazilian National Health Surveillance Agency—ANVISA (Agência Nacional de Vigilância Sanitária)—is now employing Certara’s Phoenix WinNonlin software for reviewing drug regulatory submissions.
PRINCETON, NJ – Dec. 20, 2017 – Certara today congratulated Medicines Development for Global Health (MDGH), a not-for-profit global health company, on the submission of its new drug application (NDA) for moxidectin as an oral treatment for river blindness (onchocerciasis).
PRINCETON, NJ – Dec. 8, 2017 – Certara announced that Leigh Farrell, PhD, Vice President of Corporate Strategy and Business Development, is presenting the inaugural Certara New Investigator Awards in association with the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT).
PRINCETON, NJ – Dec. 4, 2017 – Certara today announced that it has launched version 17 of its Simcyp Population-based Simulator.
PRINCETON, NJ – Nov. 14, 2017 – Certara today announced that the US Food and Drug Administration has greatly expanded its use of Certara’s PBPK Simcyp Population-based Simulator and its Pediatric and Cardiac Safety Simulators. Under the new agreement, FDA has almost tripled its number of licenses, equipping its M&S review team with almost 60 PBPK licenses.